Phase 1, Double Blind, Placebo-Controlled, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Clinical Trial of AB103, A Peptide Antagonist in Healthy Volunteers.

Trial Profile

Phase 1, Double Blind, Placebo-Controlled, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Clinical Trial of AB103, A Peptide Antagonist in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2011

At a glance

  • Drugs Reltecimod (Primary)
  • Indications Bacterial infections; Sepsis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 May 2011 Positive tolerability and pharmacokinetic results reported in an Atox Bio media release.
    • 12 May 2011 Status changed from recruiting to completed, as reported in an Atox Bio media release.
    • 15 Sep 2010 Dosing has been completed in the first subject, according to an Atox Bio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top